Radiation-induced eosinophil increase ratio predicts patient outcomes in non-small cell lung cancer

Nuo-Han Wang1, Xin Zhang2, Jiang-Dong Sui2*, Ying Wang2*, Yong-Zhong Wu2*, Qian-Qian Lei3, Hong-Lei Tu2, Li-Na Yang2, Yun-Chang Liu3, Meng-Qi Yang2, Hao-Nan Yang3, Dan Li1 and Zheng Lei1

1College of Medicine, Chongqing University, Chongqing, China, 2Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, China, 3College of Bioengineering, Chongqing University, Chongqing, China

Background and purpose: Radiotherapy (RT) is a double-edged sword in regulating immune responses. This study aimed to investigate the impact of thoracic RT on circulating eosinophils and its association with patient outcomes in non-small cell lung cancer (NSCLC).

Materials and methods: This retrospective study included 240 patients with advanced NSCLC treated with definitive thoracic RT from January 2012 to January 2020. Statistics included Kaplan-Meier analysis of overall survival (OS) and progression-free survival (PFS), multivariate Cox analyses to identify significant variables, and Spearman’s correlation to qualify the relationship between dose-volume histogram (DVH) parameters and EIR.

Results: Absolute eosinophil counts (AECs) showed an increasing trend during RT and an obvious peak in the 1st month after RT. Thresholds of eosinophil increase ratio (EIR) at the 1st month after RT for both OS and PFS were 1.43. Patients with high EIR above 1.43 experienced particularly favorable clinical outcomes (five-year OS: 21% versus 10%, P<0.0001; five-year PFS: 10% versus 8%, P=0.014), but may not derive PFS benefit from the addition of chemotherapy to RT. The higher a patient’s EIR, the larger the potential benefit in the absence of chemotherapy. DVH parameters including heart mean dose and heart V10 were negatively associated with EIR. None of these DVH parameters was correlated with the clinical outcomes.

Conclusion: EIR may serve as a potential biomarker to predict OS and PFS in NSCLC patients treated with RT. These findings require prospective studies to
evaluate the role of such prognostic marker to identify patients at risk to tailor interventions.

KEYWORDS
radiotherapy, dose-volume histogram parameters, eosinophil increase ratio, non-small cell lung cancer, Sequential chemoradiotherapy

Introduction

Radiotherapy (RT) is the most available treatment for patients with NSCLC who are not suitable for surgery and the great proportion of patients with limited-stage small cell lung cancer (SCLC). The poor survival rate of the localized lung cancer patients who received RT is due to the limited treatment delivery to tumors (1). Constrained by the radiation toxicities of adjacent organs such as uninvolved lung, heart, spinal cord, and esophagus, attempting to escalate radiation dose has failed to translate into improvements in outcome (2).

RT has long been known to induce immune system activation through the production of local inflammatory responses, increasing tumor-infiltrating immunostimulatory cells, and promoting tumor antigens to release (3–8). An effective immune response contributes to improving patient outcomes. Eosinophil, as a type of circulating immune cell, is cardinal in infiltrating multiple tumors (9) and correlates with cancer patient outcomes in distinct histological types of tumors (10, 11). High levels of eosinophils in colorectal tumor (12), nasopharyngeal carcinomas (13), and melanomas (14) correlated with better outcomes. Post-treatment absolute eosinophil counts (AECs) may be a prognostic biomarker in NSCLC, some published findings have even verified its correlation with progression-free survival (PFS) (10).

In addition to its immune-stimulating effects, radiation is also known to induce immunosuppression (15). Since the pulmonary circulation receives the entire cardiac output, a great number of circulating immune cells are directly destructed during thoracic radiation (16–18). Larger exposure to RT fields may cause larger lung volume to radiation, and as a result, induces more eosinophils destruction. Since a large volume of blood circulates through the heart during each thoracic RT fraction, therefore, the heart dose is a plausible parameter of eosinophils destruction.

We hypothesized that the fewer AECs impaired by radiation exhibited better patient outcomes through restricting heart dose-volume histogram (DVH) parameters. In addition, we investigated whether eosinophil preservation predicted benefit from the addition of chemotherapy in the homogeneous NSCLC cohort.

Material and methods

Patients

A retrospective analysis was carried out for advanced NSCLC patients who were treated with RT at a single academic cancer center between January 2012 and January 2020. Inclusion criteria: pathologic confirmation of NSCLC, stage III (Eighth edition of lung cancer stage classification), stage IV with oligometastatic disease, receipt of radical thoracic RT to the primary disease, radiation dose ≥46 Gy, with full blood counts recorded 1 week prior to initiation of RT and at least once after RT. Patients were diagnosed with acute or chronic infections, any type of immunodeficiency, hematological disorders, or anti-inflammatory treatment before RT which would affect AECs in the peripheral blood were excluded. The Ethics Committee of Chongqing University Cancer Hospital approved this retrospective study.

Data collection

Patients’ demographic data, clinicopathological characteristics and treatment conditions were further collected manually by using the hospital electronic medical record database. Variables included gender, age, ECOG PS, smoking history, TNM stage, use of corticosteroids and so on. Sequential chemoradiotherapy (s-CRT) was defined as chemotherapy delivered within 1 month before and/or after RT in this study. Chemotherapy delivered beyond 1 month before or after RT was considered as received RT alone. The complete blood cell count closest to the start of RT was chosen and taken as the baseline blood count. The AECs of baseline, during (week1, week2, week3, week4), and after (month1, month2, month3) RT were recorded.

RT modalities included intensity-modulated radiotherapy (IMRT), three-dimensional conformal radiotherapy (3D-CRT), and helical tomotherapy (TOMO). Patients included in this study were treated with standard fractionation regimes. RT dose and planning target volume (PTV) were collected directly from the treatment plans. To enhance comparability, the
radiation dose was converted to an equivalent dose in 2 Gy fractions (EQD2) assuming alpha/beta=10 for tumor. DVH parameters were obtained including body (V2, V5, V10), lung (mean dose, V2, V5, V10), and heart (mean dose, V2, V5, V10). Efficacy was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (19). Overall Survival (OS) was defined as the time from radiotherapy administration to death by any cause or the time of the last follow-up (14 July 2021). PFS was defined as the time from radiotherapy administration to the first recorded instance of disease progression, death, or last follow-up visit, whichever came first.

Statistics

Descriptive statistics were used to examine whether the data in the study followed a normal distribution. Continuous data were presented as median and interquartile range (IQR) for non-normal distribution and mean± standard deviation (SD) for normal distribution. Categorical data were compared using the χ2 test. Student t-test was applied for comparing centers of groups for continuous data. Mann Whitney U-test and Wilcoxon signed-rank test were applied for comparing centers of groups. Spearman’s correlation coefficients were used for non-normal distributive data to determine the relationship between DVH parameters and eosinophil count and quantify these associations. The continuous predictor was linear and showed no natural threshold for patient stratification, restricted cubic spline loaded in R packages were used to transform the predictor from a continuous variable into a categorical variable by deriving a cutoff value. Kaplan-Meier analyses for PFS and OS were graphed when the data were separated by the threshold of eosinophil increase ratio (EIR). Univariate and multivariable Cox regressions were applied to access the effects of patient-, tumor-, and treatment-correlated to the clinical outcomes and estimate the hazard ratio (HR) and 95% CI. Variables with a P<0.2 in the univariate analysis were included in the analysis. The median follow-up was 21 months with 149 events (62%) at the last follow-up. The clinicopathological and DVH parameters were listed in Table 1. The mean age of the population was 62 years (range 55 to 67 years), 88% of the participants were male and 25% were non-smokers. Tumors were adenocarcinoma (32%) or squamous (58%) histology, and most often T4 (52%), with N3 (48%) nodal status. The most frequent RT technique was intensity-modulated RT (86%). 124 (52%) patients received RT alone while s-CRT was used in 106 (44%) patients and only 10 (4%) were treated with concurrent CRT. The median prescribed radiation dose was delivered as 60 Gy (IQR 56 to 66 Gy) in 2-Gy fractions over a median 42-day treatment course.

Dynamic changes of AECs

To visualize patients’ peripheral blood eosinophil trends in the cohort that received RT, AECs were graphed with respect to time (referring to the start of RT until the time 3 months after RT). As shown in Figure 1, AECs overall showed an increasing trend during RT and there was a characteristic of double peaks in the 1st week during RT and the 1st month after RT for patients who received RT alone while a single peak in the 1st month after RT for patients treated with s-CRT. Given the above findings, we named the ratio of eosinophil count in the 1st month after RT to that at baseline as Eosinophil Increase Ratio (EIR), which was able to reflect the efficiency and kinetics of the radiation-induced eosinophilia.

Association between EIR and clinical outcomes

Kaplan-Meier (Log-rank) and univariate analysis revealed that significantly higher median OS and PFS were observed in the higher EIR (EIR>1.43) group than in the lower EIR (EIR ≤ 1.43) group (Five-year OS: 21% versus 10%, P<0.0001; Five-year PFS: 10% versus 8%, P=0.014 Figures 2-4). Among the 240 patients, 109 (45%) had an EIR>1.43 and the distribution of the two groups did not differ according to clinical factors (Table 1). Furthermore, in the multivariate Cox analysis, the higher EIR was an independent protective factor for OS (HR 0.541, 95% CI 0.382-0.765, P=0.0001) and PFS (HR 0.685 95% CI 0.511-0.916, P=0.012 Tables 2, 3). Altogether, the results suggested that higher EIR was associated with a good prognosis for patients who received RT.

To evaluate whether the addition of chemotherapy to RT influenced the predictive function of EIR, the cohort was grouped based on sequential chemotherapy administration. The distribution of the RT alone and s-CRT groups did not differ according to clinical factors (Supplementary Table 1). EIR
| Parameters          | All (n=240) | Eosinophil increase ratio | P-value |
|--------------------|-------------|---------------------------|---------|
|                    | High EIR Group (n=109) | Low EIR Group (n=131)    |         |
| Gender n (%)       |              |                          |         |
| Female             | 29 (12.08)  | 17 (15.60)                | 12 (9.16) | 0.129 |
| Male               | 211 (87.92) | 92 (84.40)                | 119 (90.84) |
| Age (yr) mean (SD) | 60 ± 9.28   | 60.5 ± 9.64               | 60 ± 9   |
| ECOG PS n (%)      |              |                          |         |
| 0-1                | 188 (78.33) | 85 (77.98)                | 103 (78.63) | 0.875 |
| 2-3                | 52 (21.67)  | 24 (22.02)                | 28 (21.37) |
| Smoking history n (%) |          |                          |         |
| Never              | 59 (24.58)  | 31 (28.44)                | 28 (21.37) | 0.207 |
| Current or former  | 181 (75.42) | 78 (71.56)                | 103 (78.63) |
| Histology n (%)    |              |                          |         |
| Adenocarcinoma     | 77 (32.08)  | 38 (34.86)                | 39 (29.77) | 0.721 |
| Squamous cell carcinoma | 139 (57.92) | 60 (55.05)                | 79 (60.31) |
| LCLC               | 3 (1.25)    | 2 (1.83)                  | 1 (0.76) |
| NOS                | 22 (9.17)   | 10 (9.17)                 | 12 (9.16) |
| Tumor laterality n (%) |          |                          |         |
| Left               | 94 (39.17)  | 40 (36.70)                | 54 (41.22) | 0.574 |
| Right              | 142 (59.17) | 68 (62.39)                | 74 (56.49) |
| Mediastinum        | 4 (1.67)    | 1 (0.92)                  | 3 (2.29) |
| T stage n (%)      |              |                          |         |
| 0                  | 1 (0.42)    | 1 (0.92)                  | 0 (0)   | 0.479 |
| 1                  | 11 (4.58)   | 7 (6.42)                  | 4 (3.05) |
| 2                  | 62 (25.85)  | 29 (26.61)                | 33 (25.19) |
| 3                  | 40 (16.67)  | 16 (14.68)                | 24 (18.32) |
| 4                  | 125 (52.08) | 56 (51.38)                | 69 (52.67) |
| NA                 | 1 (0.42)    | 0 (0)                     | 1 (0.76) |
| N stage n (%)      |              |                          |         |
| 0                  | 9 (3.75)    | 3 (2.75)                  | 6 (4.58) |
| 1                  | 21 (8.75)   | 11 (10.09)                | 10 (7.63) |
| 2                  | 93 (38.75)  | 43 (39.45)                | 50 (38.17) |
| 3                  | 116 (48.33) | 51 (46.79)                | 65 (49.62) |
| NA                 | 1 (0.42)    | 1 (0.92)                  | 0 (0)   | 0.745 |
| M stage n (%)      |              |                          |         |
| 0                  | 160 (66.67) | 74 (67.89)                | 86 (65.65) | 0.906 |
| 1                  | 80 (33.33)  | 35 (32.11)                | 45 (34.35) |
| TNM stage n (%)    |              |                          |         |
| III                | 160 (66.66) | 73 (30.42)                | 89 (37.08) | 0.874 |
| IV                 | 80 (33.34)  | 36 (15)                   | 42 (17.5) |
| Chemotherapy Condition n (%) | |                          |         |
| Concurrent         | 10 (4.17)   | 4 (3.67)                  | 6 (4.58) |
| Radiotherapy Alone | 124 (51.67) | 59 (54.13)                | 65 (49.62) |
| Sequential         | 106 (44.17) | 46 (42.20)                | 60 (45.8) |
| Targeted therapy n (%) |          |                          |         |
| Yes                | 20 (8.33)   | 10 (9.17)                 | 10 (7.63) | 0.668 |
| No                 | 220 (91.67) | 99 (90.83)                | 121 (92.37) |

(Continued)
was able to predict both OS and PFS of the cohort received RT alone (median OS of EIR >1.43 and ≤1.43: 34 months versus 19 months, P<0.0001, Figure 2C; median PFS of EIR >1.43 and ≤1.43: 14 months versus 11 months, P=0.0074, Figure 2E). However, in the cohort that received s-CRT, EIR predicted OS rather than PFS (median OS of EIR >1.43 and ≤1.43: 36 months versus 27 months, P=0.022, Figure 2D; median PFS of EIR >1.43 and ≤1.43: 17 months versus 11 months, P=0.33, Figure 2F). In addition, compared with the RT alone cohort, the correlation between EIR and OS was attenuated by chemotherapy administration (Figures 2C, D). The interaction between EIR and chemotherapy showed the higher a patient’s EIR, the larger the potential benefit in the absence of sequential chemotherapy (Supplementary Figure 2). Confirming these findings, multivariate Cox analyses demonstrated that EIR has significantly associated with OS in the RT alone cohort (HR 0.334, 95% CI 0.196-0.572, P<0.0001), rather than in the s-CRT cohort (Supplementary Table 2).

Association between EIR and dosimetry

Lastly, predictors of EIR determined by Spearman’s correlation analyses were shown in Supplementary Tables 3, 4. The result revealed that none of the clinicopathological factors was associated with EIR (Supplementary Table 3). To provide insight into the association between DVH parameters and EIR in the RT alone cohort. The results revealed that higher heart mean dose (r=-0.192, P=0.033) and heart V10 (r=-0.189, P=0.035) were significantly associated with lower EIR (Supplementary Table 4 and Figure 5). Of note, none of the heart mean dose and heart V10 was associated with PFS or OS (Figures 3, 4).

**TABLE 1 Continued**

| Parameters | All (n=240) | Eosinophil increase ratio |
|------------|-------------|---------------------------|
| Corticosteroid therapy n (%) | | 0.521 |
| Yes | 183 (76.25) | 81 (74.31) | 102 (77.86) |
| No | 57 (23.75) | 28 (25.69) | 29 (22.14) |
| Radiotherapy modality n (%) | | 0.361 |
| 3D-CRT | 14 (5.83) | 7 (6.42) | 7 (5.34) |
| TOMO | 18 (7.5) | 10 (9.17) | 8 (6.11) |
| IMRT | 208 (86.67) | 92 (84.40) | 116 (88.55) |
| PTV, median (IQR) | 385.75 (281.125-568.2) | 377.3 (270.1-527) | 389.6 (291.6-591.7) |
| EQD2 (Gy), median (IQR) | 60 (56-66) | 60 (56-66) | 60 (54-65.69) |
| Radiation duration (Days), median (IQR) | 42 (38-45) | 42 (37.5-44) | 42 (38-46) |

NSCLC, non-small cell lung cancer; LCLC, large cell lung cancer; NOS, not otherwise specified; ECOG PS, Eastern Cooperative Oncology Group performance status; SD, standard deviation; IQR, interquartile range; EIR, eosinophil increase ratio.
Discussion

To the best of our knowledge, this is the first report that uses EIR to predict PFS and OS benefit from RT for patients with advanced NSCLC. A high EIR is a beneficial prognostic factor for patients receiving RT alone but is attenuated by s-CRT. This study also reports that the heart mean dose and heart V10 were significantly associated with the decline of peripheral blood eosinophils. However, these DVH parameters do not independently associate with PFS or OS. Therefore, restriction of heart DVH parameters could indirectly affect patients’ clinical outcomes by means of retarding eosinophils decline in patients receiving RT.

A growing body of literature has manifested the fact that high eosinophil counts could positively affect the efficacy of immunotherapy in head and neck squamous cell carcinoma (20), NSCLC (21), and melanoma (22) due to its potentially antitumorigenic functions and contribution to the infiltration and activation of other immune cells into tumors (7, 9). However, utilizing pre- or post-treatment AECs to predict clinical benefits could not reflect whether the dynamic change of AECs caused by treatment affects patient outcomes. In addition, in a recent study of 234 NSCLC cases managed with definitive RT, patients with higher eosinophil counts after radiation had a longer PFS (HR 0.73, P=0.0294) (10). However, the main limitation in this study was that the median intervals from baseline to peak eosinophil counts were different in their two NSCLC cohorts (one cohort was 15 days, another was 37 days), suggesting obvious heterogeneity between
these two groups; moreover, the eosinophil peak time point of each individual was inconsistent and even extended to 5 months after RT in some cases, which would confound the effect of RT.

The strength of our study was that we used EIR, the ratio of eosinophil count in the 1st month after RT to that at baseline, to reflect the dynamic change before and after RT. There was an early peak of eosinophil count in the 1st week during RT for patients who received RT alone, but not s-CRT, and the predictive role that EIR played regarding to OS was attenuated by chemotherapy administration. All the baseline characteristics
FIGURE 5

Spearman's correlation coefficient between DVH parameters and EIR at varying percentages of body, lung, and heart doses for patients who received RT alone.

TABLE 2 Multivariable Cox regression analyses of PFS for advanced NSCLC cohort.

| Parameters                        | Advanced NSCLC cohort (n=240) |  |  |  |
|-----------------------------------|------------------------------|---|---|---|
|                                   | P-value |  | HR (Univariate, 95% CI) |  | AHR (Multivariable, 95% CI) |
| Heart V2 Median (IQR)             | 0.048   | 0.995 (0.990-1.000) | 0.022 | 0.994 (0.989-0.999) |
| Eosinophil Increase Ratio (EIR)   | 0.59 (0.19-0.97) | – | – | – |
| Eosinophil Increase Ratio (EIR)   | 3.2 (2.00-5.33) | 0.018 | 0.704 (0.527-0.942) | 0.012 | 0.685 (0.511-0.916) |

NSCLC, non-small cell lung cancer; SD, standard deviation; IQR, interquartile range; HR, hazard ratio; AHR, adjusted hazard ratio; CI, confidence interval.

TABLE 3 Univariate and multivariable Cox regression analyses of OS for advanced NSCLC cohort.

| Parameters                        | Advanced NSCLC cohort (n=240) |  |  |  |
|-----------------------------------|------------------------------|---|---|---|
|                                   | n (%)/mean (SD)/median (IQR) | P-value | HR (Univariate, 95% CI) |  | AHR (Multivariable, 95% CI) |
| Gender Female                     | 29 (12.8) | – | – | – |
| Age Mean (SD)                     | 60 ± 9.28 | 0.061 | 1.017 (0.999-1.036) | 0.022 | 1.025 (1.004-1.046) |
| TNM Stage III                     | 160 (66.67) | – | – | – |
| Chemotherapy Condition Concurrent | 124 (51.67) | 0.03 | 3.579 (1.128-11.352) | 0.019 | 4.065 (1.136-13.070) |
| Chemotherapy Condition Sequential | 106 (44.17) | 0.09 | 2.734 (0.856-8.731) | 0.035 | 3.499 (1.090-11.232) |
| PTV Volume Median (IQR)           | 385.75 (281.125-568.2) | 0.001 | 1.001 (1.000-1.001) | 0.0001 | 1.001 (1.000-1.001) |
| Eosinophil Increase Ratio (EIR) Low (≤1.43) | 0.59 (0.19-0.97) | – | – | – |
| Eosinophil Increase Ratio (EIR) High (>1.43) | 3.2 (2.00-5.33) | 0.001 | 0.560 (0.402-0.780) | 0.0001 | 0.541 (0.382-0.765) |

NSCLC, non-small cell lung cancer; SD, standard deviation; IQR, interquartile range; HR, hazard ratio; AHR, adjusted hazard ratio; CI, confidence interval; PTV, planning target volume.
between RT alone group and s-CRT group did not differ, meaning that the predictive power of EIR was affected by chemotherapy, rather than pre-existing differences. The interaction between EIR and chemotherapy showed the higher a patient’s EIR, the larger the potential benefit in the absence of sequential chemotherapy. We can infer that enough time interval is needed after RT for the recovery of eosinophil until EIR exceeds 1.43 before subsequent chemotherapy administration. Moreover, the adequate time interval between induction chemotherapy and RT, and the fewer chemotherapy cycles before RT may facilitate a better survival outcome by means of retarding eosinophils decline.

Since a large volume of blood flowed through the heart, thoracic radiation can impair circulating immune cells. Several pieces of evidence had studied the severe lymphopenia associated with DVH, treatment and clinical factors (23–25). A meta-analysis suggested that gross tumor volume, lung V5 and heart V5 were predictive of lymphopenia by pooling 10 quantitative studies (26). Consistently, our study is the first to investigate the interaction between DVH parameters and the change of eosinophils. The results showed that heart mean dose and heart V10 were significantly negatively associated with EIR. Thus, we should minimize the heart DVH parameters as low as possible to optimize RT treatment plan.

This study has limitations, including those inherent in retrospective reviews. The eosinophils from our study were not isolated for further characterization of their phenotypes, and the heterogeneity of protumorigenic and antitumorigenic eosinophil phenotypes could not be evaluated in our study. In addition, the association between low EIR and survival would warrant further investigations. It is possible that the low EIR results in a poor immune status or induces radiation-related toxicity profiles. Furthermore, all patients in our study were Chinese individuals treated with RT alone or s-CRT. Our findings may not be generalizable to other populations with different treatment modalities and racial backgrounds.

In conclusion, our study’s findings suggested that EIR was an independent prognostic factor for survival outcomes among patients with NSCLC undergoing RT. Further studies would be warranted to tailor treatments based on the risk stratification by EIR.

### Ethics statement

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

### Author contributions

Equal contribution and first authorship: N-HW and XZ contributed equally to this work and share first authorship.

### Funding

We thank all the members of the Radiation Oncology Translational Research Group (ROTRG) who participated in this study. The current study was supported by grants from the National Natural Science Foundation of China (No. 81972857 to YW; No. 82073347 to Y-ZW), Chongqing Science and Health Joint Medical Research Project (No. 2022ZDXM028 to J-DS), Natural Science Foundation of Chongqing City (No. cstc2021jcxjB165 to Y-ZW; No. cstc2021jcx-msxm0029 to YW; No. cstc2021jcxyx-0587 to H-LT; No. cstc2019jcxyx-0648 to Q-QL), and Integrated innovation and application of key technologies for precise prevention and treatment of primary lung cancer (No.2019ZZX002 to Y-ZW).

### Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

### Supplementary material

The Supplementary Material for this article can be found online at: [https://www.frontiersin.org/articles/10.3389/fonc.2022.999555/full#supplementary-material](https://www.frontiersin.org/articles/10.3389/fonc.2022.999555/full#supplementary-material)

### Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

### References

1. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995–2009: Analysis of individual data for 35,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet (2015) 385:977–1010. doi: 10.1016/S0140-6736(14)62038-9

2. Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): An open-label, phase 3, randomised, superiority trial. Lancet Oncol (2017) 18:1116–25. doi: 10.1016/S1470-2045(17)30318-2
1. Fujii M, Yamashita T, Ishiguro R, Tashiro M, Kameyama K. Significance of epidermal growth factor receptor and tumor associated tissue eosinophils in the prognosis of patients with nasopharyngeal carcinoma. *Auris Nasus Larynx* (2002) 29:175–81. doi: 10.1016/S0385-8146(01)00135-3

2. Martens A, Wistuba-Hamprecht K, Geukes Poppen M, Yuan J, Postow MA, Wong P, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. *Clin Cancer Res* (2016) 22:2908–18. doi: 10.1158/1078-0432.CCR-15-2412

3. McLaughlin M, Patin EC, Pedersen M, Wilkins A, Dillon MT, Melcher AA, et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. *Nat Rev Cancer* (2020) 20:203–17. doi: 10.1038/s41568-020-0246-1

4. Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within microcranes. *Nature* (2017) 548:466–70. doi: 10.1038/nature23470

5. Dillon MT, Bergerhoff KE, Pedersen M, Whitlock H, Crespo-Rodrigues E, Patin EC, et al. ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment. *Clin Cancer Res* (2019) 25:3392–403. doi: 10.1158/1078-0432.CCR-18-1821

6. Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhude SA, Newbold KL, et al. Radiosensitization by the ATR inhibitor AZD6738 through generation of acetic microcane. *Mol Cancer Ther* (2017) 16:25–34. doi: 10.1158/1355-7163.MCT-16-0239

7. Carretto R, Sekioglu JM, Garbi N, Salgado OC, Beckhove P, Hammerling GI. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells. *Nat Immunol* (2015) 16:609–17. doi: 10.1038/ni.3159

8. Brandmaier A, Formenti SC. The impact of radiation therapy on innate and adaptive tumor immunity. *Semin Radiat Oncol* (2020) 30:139–44. doi: 10.1016/j.semradonc.2019.12.005

9. Grisurol-Tal S, Itan M, Klion AD, Munitz A. A new dawn for eosinophils in the tumour microenvironment. *Nat Rev Cancer* (2020) 20:594–607. doi: 10.1038/s41568-020-0283-9

10. Cheng JN, Luo W, Sun C, Jin Z, Zeng X, Alexander PB, et al. Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy. *Sci Adv* (2021) 7:eabc7609. doi: 10.1126/sciadv.abc7609

11. von Weizsäcker R, Seh K, Franklin J, Fischer R, Huber K, Hansmann ML, et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin’s disease, allowing for known prognostic factors. *Blood* (2000) 95:1207–13. doi: 10.1182/blood.V95.4.1207.004354.1207_1213

12. Nielsen HJ, Hansen U, Christensen II, Reutert CM, Brünner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. *J Pathol* (1999) 189:487–95. doi: 10.1002/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-I

13. Fuji M, Yamashita T, Ishiguro R, Tashiro M, Kameyama K. Significance of epidermal growth factor receptor and tumor associated tissue eosinophils in the prognosis of patients with nasopharyngeal carcinoma. *Auris Nasus Larynx* (2002) 29:175–81. doi: 10.1016/S0385-8146(01)00135-3

14. Martens A, Wistuba-Hamprecht K, Geukes Poppen M, Yuan J, Postow MA, Wong P, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. *Clin Cancer Res* (2016) 22:2908–18. doi: 10.1158/1078-0432.CCR-15-2412

15. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: A paradigm shift. *J Natl Cancer Inst* (2013) 105:256–65. doi: 10.1093/jnci/djt062

16. Falcke SE, Ruhle PF, Deloch L, Fietkau R, Frey B, Gaipl US. Clinically relevant radiation exposure differentially impacts forms of cell death in human cells of the innate and adaptive immune system. *Int J Mol Sci* (2018) 19(11):3574. doi: 10.3390/ijms19113574

17. Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related pneumonitis in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. *Cancer Invest* (2013) 31:140–4. doi: 10.1080/07357907.2012.762780

18. Wirsdorf F, Jendrossek V. The role of lymphocytes in radiotherapy-induced adverse late effects in the lung. *Front Immunol* (2016) 7:591. doi: 10.3389/fimmu.2016.00591

19. Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekas S, et al. RECIST 1.1 update and clarification: From the RECIST committee. *Eur J Cancer* (2016) 62:132–7. doi: 10.1016/j.ejca.2016.03.081

20. Nishikawa D, Suzuki H, Beppu S, Terada H, Sawabe M, Kadowaki S, et al. Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab. *Cancer Sci* (2021) 112:339–46. doi: 10.1111/cas.14706

21. Chu X, Zhao J, Zhou J, Zhou P, Jiang T, Jiang S, et al. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. *Lung Cancer* (2020) 156:76–82. doi: 10.1016/j.lungcan.2020.08.015

22. Gebhardt C, Serko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. *Clin Cancer Res* (2015) 21:5453–9. doi: 10.1158/1078-0432.CCR-15-0676

23. Abravanel A, Faire-Finn C, Kennedy J, McWilliam A, van Herk M. Radiotherapy-related pneumonitis affects overall survival in patients with lung cancer. *J Thorac Oncol* (2020) 15:1624–35. doi: 10.1016/j.jtho.2020.06.008

24. Chen D, Patel RB, Verma V, Ramapriyan R, Barsoumian HB, Csorta MA, et al. Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. *Radiother Oncol* (2020) 150:114–20. doi: 10.1016/j.radonc.2020.05.051

25. Joseph N, McWilliam A, Kennedy J, Hulett K, Mahé J, Gavattaraj A, et al. Post-treatment lymphocytopenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy. *Radiother Oncol* (2019) 135:115–9. doi: 10.1016/j.radonc.2019.03.088

26. Upadhyay R, Venkatesulu BP, Giridhar P, Kim BK, Sharma A, Elghazawy H, et al. Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis. *Radiother Oncol* (2021) 157:225–33. doi: 10.1016/j.radonc.2021.01.034